Lantern Pharma (NASDAQ: LTRN) reported its second-quarter 2026 operational and financial results, showcasing significant progress across its AI-driven oncology pipeline and the establishment of Open Medicine AI (OMAI) as a separate company. The company highlighted emerging data from the Phase 2 HARMONIC trial of LP-300, which showed deepening progression-free survival benefit with treatment duration in patients with EGFR exon 21 L858R mutations. Additionally, the FDA reviewed key protocol amendments without objection, and the European Medicines Agency cleared an investigator-initiated Phase 1b/2 trial of LP-184 (zirdafulven) in biomarker-selected advanced bladder cancer.
The company also received a Notice of Allowance from the U.S. Patent and Trademark Office covering a three-gene patient-selection signature for LP-184. In August, Lantern established OMAI as a wholly owned subsidiary and entered into board-approved commercial licensing agreements for its multi-agentic AI co-scientist platform, previously launched as withZeta.ai. This move positions OMAI to independently commercialize the AI platform, potentially unlocking new revenue streams for Lantern.
Financially, Lantern reported a second-quarter loss from operations of approximately $3.5 million, down about 25% from $4.7 million in the same period last year. Research and development expenses declined 42% to approximately $1.8 million. The net loss was approximately $7.1 million, or $0.57 per share, compared with $4.3 million, or $0.40 per share, a year earlier. The increase was largely due to approximately $3.6 million in warrant-related expense. As of June 30, 2026, the company held cash, cash equivalents, and marketable securities totaling approximately $7.4 million.
The establishment of OMAI as a separate entity is a strategic move that could allow the AI platform to attract its own investment and partnerships, potentially accelerating its adoption in the biomedical and drug development community. The withZeta.ai platform is now commercially available as a subscription-based research platform, representing a new revenue stream for the company. This diversification aligns with Lantern's broader mission to leverage AI and machine learning to transform cancer therapy development.
Lantern Pharma continues to advance its clinical pipeline, including LP-184, LP-284, and LP-300, with a focus on precision oncology. The company's proprietary RADR platform remains central to its drug development strategy, enabling the identification of patient populations most likely to benefit from its therapies. With ongoing trials and regulatory progress, Lantern is positioning itself as a leader in AI-driven oncology.
For more information, visit the company's newsroom at https://nnw.fm/LTRN.
